Literature DB >> 17200672

Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.

Bing Xia1, Josephine C Dorsman, Najim Ameziane, Yne de Vries, Martin A Rooimans, Qing Sheng, Gerard Pals, Abdellatif Errami, Eliane Gluckman, Julian Llera, Weidong Wang, David M Livingston, Hans Joenje, Johan P de Winter.   

Abstract

The Fanconi anemia and BRCA networks are considered interconnected, as BRCA2 gene defects have been discovered in individuals with Fanconi anemia subtype D1. Here we show that a defect in the BRCA2-interacting protein PALB2 is associated with Fanconi anemia in an individual with a new subtype. PALB2-deficient cells showed hypersensitivity to cross-linking agents and lacked chromatin-bound BRCA2; these defects were corrected upon ectopic expression of PALB2 or by spontaneous reversion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17200672     DOI: 10.1038/ng1942

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  221 in total

1.  Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States.

Authors:  Yuan Chun Ding; Linda Steele; Chih-Jen Kuan; Scott Greilac; Susan L Neuhausen
Journal:  Breast Cancer Res Treat       Date:  2010-10-07       Impact factor: 4.872

2.  Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated.

Authors:  Femme Harinck; Irma Kluijt; Saskia E van Mil; Quinten Waisfisz; Theo A M van Os; Cora M Aalfs; Anja Wagner; Maran Olderode-Berends; Rolf H Sijmons; Ernst J Kuipers; Jan-Werner Poley; Paul Fockens; Marco J Bruno
Journal:  Eur J Hum Genet       Date:  2011-12-14       Impact factor: 4.246

3.  Novel germline PALB2 truncating mutations in African American breast cancer patients.

Authors:  Yonglan Zheng; Jing Zhang; Qun Niu; Dezheng Huo; Olufunmilayo I Olopade
Journal:  Cancer       Date:  2011-08-26       Impact factor: 6.860

Review 4.  Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes.

Authors:  Marina Pajic; Christopher J Scarlett; David K Chang; Robert L Sutherland; Andrew V Biankin
Journal:  Hum Genet       Date:  2011-04-23       Impact factor: 4.132

5.  ChAM, a novel motif that mediates PALB2 intrinsic chromatin binding and facilitates DNA repair.

Authors:  Jean-Yves Bleuyard; Rémi Buisson; Jean-Yves Masson; Fumiko Esashi
Journal:  EMBO Rep       Date:  2012-02-01       Impact factor: 8.807

6.  Fanconi anemia (FA) binding protein FAAP20 stabilizes FA complementation group A (FANCA) and participates in interstrand cross-link repair.

Authors:  Justin Wai Chung Leung; Yucai Wang; Ka Wing Fong; Michael Shing Yan Huen; Lei Li; Junjie Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-06       Impact factor: 11.205

7.  The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Authors:  Xiaozhe Wang; David T Weaver
Journal:  Am J Cancer Res       Date:  2010-01-03       Impact factor: 6.166

8.  MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks.

Authors:  Tomohiro Hayakawa; Fan Zhang; Noriyo Hayakawa; Yasuko Ohtani; Kaori Shinmyozu; Jun-ichi Nakayama; Paul R Andreassen
Journal:  J Cell Sci       Date:  2010-04-01       Impact factor: 5.285

9.  MDC1 and RNF8 function in a pathway that directs BRCA1-dependent localization of PALB2 required for homologous recombination.

Authors:  Fan Zhang; Gregory Bick; Jung-Young Park; Paul R Andreassen
Journal:  J Cell Sci       Date:  2012-10-04       Impact factor: 5.285

Review 10.  Fanconi anaemia and the repair of Watson and Crick DNA crosslinks.

Authors:  Molly C Kottemann; Agata Smogorzewska
Journal:  Nature       Date:  2013-01-17       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.